Special Issue

Endocrine Diseases and Pharmacogenomics

Message from the Guest Editors

The integration of pharmacogenomics into the treatment of endocrine diseases, including Congenital Adrenal Hyperplasia (CAH), Maturity Onset Diabetes of the Young (MODY), Multiple Endocrine Neoplasia Type 2 (MEN2), Pseudohypoparathyroidism (PHP), Thyroid Hormone Resistance (THR), and others, shows significant potential to personalize treatment. This approach aims to optimize the use of clinically relevant drugs and enables personalized therapies for inherited endocrine disorders, improving efficacy and minimizing adverse effects. Despite promising research, much of this field's potential remains unexploited. Many pharmacogenetic findings need validation through large, well-designed clinical trials to confirm their relevance. The complexity of gene–drug interactions and diverse patient populations highlights the need for robust studies to turn discoveries into practical treatments. This Special Issue aims to explore any aspect of the search for endocrine treatments informed by pharmacogenomics. Contributions in the form of opinions, brief reports, communications, research articles, and reviews are welcomed.

Guest Editors

Prof. Dr. Leonidas A. Phylactou

Dr. Vassos Neocleous

Dr. Pavlos Fanis

Deadline for manuscript submissions

25 October 2025

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/227223

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceutical

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI